Valuation: Ligand Pharmaceuticals Incorporated

Market Cap 6.33B 5.55B 5.12B 4.74B 8.98B 606B 9.16B 61.61B 23.94B 297B 23.77B 23.24B 1,029B P/E 2026 *
71.5x
P/E 2027 * 37.8x
Enterprise Value 6.33B 5.55B 5.12B 4.74B 8.98B 606B 9.16B 61.61B 23.94B 297B 23.77B 23.24B 1,029B EV / Sales 2026 *
21.8x
EV / Sales 2027 * 16.8x
Free-Float
97.63%
Yield 2026 *
-
Yield 2027 * -
1 day-0.48%
1 week+1.87%
Current month+0.56%
1 month+33.69%
3 months+52.75%
6 months+58.87%
Current year+68.11%
1 week 308.76
Extreme 308.76
326.63
1 month 237
Extreme 237
326.63
Current year 175.89
Extreme 175.89
326.63
1 year 116.44
Extreme 116.44
326.63
3 years 49.24
Extreme 49.24
326.63
5 years 49.24
Extreme 49.24
326.63
10 years 49.24
Extreme 49.24
326.63
Manager TitleAgeSince
Chief Executive Officer 66 05/12/2022
Director of Finance/CFO 47 21/05/2015
Director of Finance/CFO 56 01/11/2022
Director TitleAgeSince
Chairman 76 01/03/2003
Director/Board Member 58 27/09/2006
Director/Board Member 66 01/03/2007
Date Insider Type Main position Quantity % Market Cap.
07-01Fiscal year

General Counsel

15,000 0.0748%
06-30Others

Chief Financial Officer

17 0.0001%
06-30Others

Chief Executive Officer

132 0.0007%
Change 5-day change 1-year change 3-year change Capi.($)
-0.48%+1.87%+176.10%+355.05% 6.33B
-1.07%+2.94%+57.75%+170.72% 1,102B
-0.54%+4.59%+70.51%+66.54% 643B
-0.40%+1.12%+33.78%+88.77% 450B
-1.35%+1.86%+29.96%+26.26% 336B
-0.71%+0.72%+28.85%+46.77% 288B
-1.31%-0.26%-28.18%-39.13% 222B
-0.12%+2.05%+24.16%+64.09% 199B
-0.96%+7.74%+22.20%+79.31% 169B
+0.31%+1.24%-5.64%-32.24% 137B
Average -0.62%+2.14%+40.95%+82.61% 355.15B
Weighted average by Cap. -0.72%+2.07%+40.89%+86.84%

Financials

2026 *2027 *
Net sales 290M 254M 235M 217M 412M 27.78B 420M 2.82B 1.1B 13.6B 1.09B 1.07B 47.2B 376M 329M 304M 281M 533M 35.97B 543M 3.66B 1.42B 17.6B 1.41B 1.38B 61.1B
Net income 94.91M 83.24M 76.85M 71.02M 135M 9.09B 137M 924M 359M 4.45B 356M 349M 15.44B 182M 160M 148M 136M 258M 17.45B 264M 1.77B 689M 8.54B 684M 669M 29.64B
Net Debt - -
Logo Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. It does this by financing, licensing its technologies or both. It operates two infrastructure-light royalty-generating IP platform technologies. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled FDA-approved products, including Gilead’s Veklury, Amgen’s Kyprolis, Baxter’s Nexterone, and Acrotech Biopharma’s Evomela. Its NITRICIL platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a range of indications. Its technologies also include HepDirect, LTP, and Pelican Expression Technology. It has multiple alliances, licenses and other business relationships with various pharmaceutical companies.
Employees
47
Date Price Change Volume
08/07/26 $318.15 -0.40% 241,968
07/07/26 $319.43 -0.31% 316,475
06/07/26 $320.42 +0.27% 349,436
02/07/26 $319.55 +2.42% 368,156
01/07/26 $312.01 -1.29% 521,622
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
319.43USD
Average target price
285.30USD
Spread / Average Target
-10.68%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LGND Stock